Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - IN

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy


Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy

PR Newswire

COLORADO SPRINGS, Colo., Aug. 4, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is announcing that through its wholly-owned subsidiary, Cannabis Science International Holding BV, has signed an agreement with the prestigious Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy. The agreement provides for toxicity and efficacy studies of cannabinoid formulations performed in animal models for neurobehavioral diseases including sleep disorders.

The first formulation in the series of neurobehavioral disorder-targeted products is in the pre-clinical development stage.

"We are excited to be initiating research on cannabinoids with Cannabis Science; the preliminary results are promising," said Marco Malavolta, the INRCA researcher in charge of the pre-clinical study.  Dr. Malavolta is an expert in the field of nutrition, ageing and longevity and he is currently conducting research with Dr. Mauro Provinciali (Head of Laboratory) on nutritional factors that affect cellular aging, a process also known as cellular senescence. They are undergoing their research at the Nutrition and Ageing Centre of the Scientific and Technological Pole of INRCA, a department with a long historical background in multiple aspects of gerontology research.

"We appreciate the scientific input from the INRCA colleagues in Italy and hope that we will be able to transition into clinical this program next year," noted Mario Lap, Director and President of European Operations, Cannabis Science, Inc.

About the Institute for Research, Hospitalization and Health (IRCCS)
The Italian Institute for Health and Science on Ageing (INRCA) works in the area of geriatrics and gerontology studies, with the aim of protecting the health of the elderly.  INRCA not only serves as a health resource of excellence but also supports research on basic mechanisms of longevity, the fragility of the elderly and the determinants of genetic, biological and environmental impacts of major age-related diseases. In this context, among the primary objectives of the Institute is to develop innovative and interdisciplinary research in the areas of basic biomedical, clinical, social, and organization of services.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824

Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

SOURCE Cannabis Science, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here